Medical Product Alert – Falsified IMFINZI (durvalumab) Injection 500mg
Port of Spain, May 22, 2025: The Ministry of Health (MoH), via its Chemistry Food and Drug Division, advises ofthe WHO Medical Product Alert of three batches of falsified IMFINZI (durvalumab) injection 500mg/10ml.
IMFINZI is a sterile concentrate for infusion. It contains the active pharmaceutical ingredient durvalumab, which is a monoclonal antibody. As monotherapy, it is indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC) in adults.
The WHO Alert stated that the falsified products have been detected in the Islamic Republic of Iran and Türkiye. The alert further stated that the falsified products should be considered unsafe, and their use may be life-threatening in some circumstances. The use of these falsified IMFINZI injections may lead to ineffective or delayed treatment. It is important to detect and remove any falsified IMFINZI (durvalumab) injections from circulation to prevent harm to patients.
These products are falsified as they deliberately misrepresent their identity, composition, and source. The genuine manufacturer, AstraZeneca, has identified multiple discrepancies that can be identified on the packaging of the falsified products. AstraZeneca has confirmed that the products mentioned in this alert are indeed falsified.
The public should note the lots below, as identified by the WHO alert:
- Lot BAZR – This is a genuine lot number for distribution only in India. The falsified product shows discrepancies in the packaging artwork and text placement, with some text missing.
- Lot BBEG – This is a genuine lot number for distribution only in Egypt. The falsified product shows discrepancies in the packaging artwork and text placement, with some text missing. The product price (in Egyptian Pounds) is also missing.
- Lot AVZT – This lot number is not recognized by the genuine manufacturer. Any IMFINZI product with this lot number is considered falsified”.
The product, IMFINZI (durvalumab) Injection 500mg, is registered for use in Trinidad and Tobago and therefore, out of an abundance of caution, the Ministry advises persons who may be in possession of the drug bearing lot numbers as above to discontinue use immediately and to return to the place of purchase where possible.
Additional information can be obtained by contacting the Office of the Chemistry Food and Drug Division at (868) 217-4664 Ext. 13121.
